Document is current
Any future updates will be listed below
-
Authors
Amisaki, Masataka https://orcid.org/0000-0003-4153-4036
Zebboudj, Abderezak https://orcid.org/0000-0002-4708-5211
Yano, Hiroshi https://orcid.org/0000-0002-3098-2629
Zhang, Siqi Linsey https://orcid.org/0009-0001-4436-2746
Payne, George
Chandra, Adrienne Kaya
Yu, Rebecca
Guasp, Pablo https://orcid.org/0000-0002-3655-916X
Sethna, Zachary M.
Ohmoto, Akihiro
Rojas, Luis A. https://orcid.org/0000-0001-9218-4086
Cheng, Charlotte
Waters, Theresa
Solovyov, Alexander
Martis, Stephen https://orcid.org/0000-0003-1735-2347
Doane, Ashley S.
Reiche, Charlotte
Bruno, Emmanuel M. https://orcid.org/0000-0003-2885-1133
Milighetti, Martina https://orcid.org/0000-0003-4170-8796
Soares, Kevin https://orcid.org/0000-0002-0406-017X
Odgerel, Zagaa
Moral, John Alec
Zhao, Julia N. https://orcid.org/0000-0002-4352-7748
Gönen, Mithat https://orcid.org/0000-0001-8683-8477
Gardner, Rui https://orcid.org/0000-0002-7270-5136
Tumanov, Alexei V.
Khan, Abdul G.
Vergnolle, Olivia https://orcid.org/0000-0001-6885-6145
Nyakatura, Elisabeth K.
Lorenz, Ivo C.
Baca, Manuel
Patterson, Erin
Greenbaum, Benjamin https://orcid.org/0000-0001-6153-8793
Artis, David https://orcid.org/0000-0002-1753-4100
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
Balachandran, Vinod P. https://orcid.org/0000-0002-2956-223X
- License Information
-
More Information
Article History
Received: 25 October 2021
Accepted: 19 November 2024
First Online: 15 January 2025
Competing interests
: O.V., E.K.N., I.C.L., M.B. and A.G.K. (employees of the Tri-Institutional Therapeutics Discovery Institute) may benefit from the further development and licensure of molecules described here. L.A.R. is listed as an inventor of a patent related to oncolytic viral therapy. V.P.B. reports honoraria from Genentech, and Abbvie, research support from Bristol Myers Squibb and Genentech, has consulted for Merck and is listed as an inventor on a patent application related to the use of IL-33 and enhanced IL-33 for cancer immunotherapy. T.M. reports that he is a consultant for Daiichi Sankyo, Leap Therapeutics, Immunos Therapeutics and Pfizer, and co-founder of Imvaq Therapeutics. T.M. has equity in Imvaq therapeutics. T.M. has received research funding from Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea Therapeutics, and currently receives research funding from Bristol-Myers Squibb, Enterome SA and Realta Life Sciences. T.M. is listed as an inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. D.A. has contributed to scientific advisory boards at Pfizer, Takeda, FARE and the KRF. The other authors declare no competing interests.
